Literature DB >> 3958475

Alterations in relative proportions of microheterogenous forms of human alpha 1-acid glycoprotein in liver disease.

N Serbource-Goguel Seta, G Durand, M Corbic, J Agneray, J Fegar.   

Abstract

To determine whether liver damage correlates with typical changes in alpha 1-acid glycoprotein (alpha 1-AGP) carbohydrate branching, we selected patients with liver disease determined by histological liver findings. The severity of their illness was assessed by a clinical classification depending on the presence singly or together of four clinical complications (jaundice, ascites, hepatic encephalopathy and weight loss). An alpha 1-AGP crossed immunoelectrophoresis with Concanavalin A, an easy-to-perform method, revealed 3 or 4 subpopulations, the areas of which were calculated. A ratio R was determined as the most anodic peak area relative to the other ones. In our experimental conditions a ratio R value exceeding 1 correlated with the presence of one or more clinical complications. These results, evidencing fluctuations in the proportion of the carbohydrate variants of alpha 1-AGP, lead us to propose such a ratio as an index for grading liver damage. The sensitivity of this test was 86% and its specificity was 83%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3958475     DOI: 10.1016/s0168-8278(86)80083-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

1.  Variation of alpha 1-antitrypsin glycoprotein microheterogeneity in hepatic postresuscitation disease.

Authors:  K Heyne; F K Tegtmeyer; S Weidinger
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

3.  Variations in the rate of secretion of different glycosylated forms of rat alpha 1-acid glycoprotein.

Authors:  A Drechou; J D Rouzeau; J Feger; G Durand
Journal:  Biochem J       Date:  1989-11-01       Impact factor: 3.857

4.  Effect of cytokines on glycosylation of acute phase proteins in human hepatoma cell lines.

Authors:  A Mackiewicz; D Schultz; J Mathison; M Ganapathi; I Kushner
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

Review 5.  Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function.

Authors:  W van Dijk; E C Havenaar; E C Brinkman-van der Linden
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

6.  Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.

Authors:  E Snoeck; A Van Peer; M Sack; M Horton; G Mannens; R Woestenborghs; R Meibach; J Heykants
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

7.  Prevalence of tri- and tetraantennary glycans of human alpha 1-acid glycoprotein in release of macrophage inhibitor of interleukin-1 activity.

Authors:  P N Bories; J Feger; N Benbernou; J D Rouzeau; J Agneray; G Durand
Journal:  Inflammation       Date:  1990-06       Impact factor: 4.092

8.  Changes in serum glycoprotein glycosylation during experimental inflammation in mice are general, unrelated to protein type, and opposite changes in man and rat: studies on mouse serum alpha 1-acid glycoprotein, alpha 1-esterase, and alpha 1-protease inhibitor.

Authors:  P M Heegaard
Journal:  Inflammation       Date:  1992-12       Impact factor: 4.092

Review 9.  Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer.

Authors:  A Mackiewicz; K Mackiewicz
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.